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In the last 5 years, Brazil has accounted for ≈70% of
reported dengue fever cases in the Americas. We analyzed
trends of dengue and dengue hemorrhagic fever (DHF)
from the early 1980s to 2002 by using surveillance data
from the Brazilian Ministry of Health. Two distinct epidemi-
ologic patterns for dengue were observed: localized epi-
demics (1986–1993), and endemic and epidemic virus
circulation countrywide (1994–2002). Currently, serotypes
1, 2, and 3 cocirculate in 22 of 27 states. Dengue and DHF
affected mainly adults; however, an increase in occurrence
of DHF among children has been recently detected in
northern Brazil, which suggests a shift in the occurrence of
severe disease to younger age groups. In 2002, hospital-
izations increased, which points out the change in disease
severity compared to that seen in the 1990s. We describe
the epidemiology of dengue in Brazil, characterizing the
changing patterns of it and DHF during the last 20 years.
B
razil accounted for nearly 70% of the 3,141,850
reported cases of dengue fever in the American
regions in the last 5 years (1). Dengue fever and a severe
manifestation of the illness known as dengue hemorrhagic
fever/dengue shock syndrome (DHF/DSS) are increasing-
ly important health, environmental, and economic con-
cerns in the Americas (2,3). Dengue/DHF is a febrile
illness caused by a flavivirus with four known serotypes
(dengue virus [DENV]1, 2, 3, 4), and infection is mainly
transmitted by the mosquito Aedes aegypti (4). Currently,
no vaccine is available for dengue fever, and disease con-
trol and prevention have mainly focused on vector control
activities and surveillance that incorporates community
participation (5,6). Despite vector control programs and
heightened public awareness, outbreaks have occurred in
several highly urbanized areas in Central and South
America (7–9).
The reemergence of dengue in Latin America occurred
during the 1960s with epidemics in the Caribbean and
Venezuela and in the 1970s in Colombia (3). Brazil
remained free of A. aegypti until 1976 as a result of the
successful eradication program to prevent urban yellow
fever coordinated by the Pan American Health
Organization (PAHO) in previous decades (10,11). The
subsequent reinfestation of A. aegypti into urban areas of
Brazil and the introduction of DENV in 1986 led to resur-
gence of dengue fever outbreaks and an increased risk for
urbanization of yellow fever in the country (12). 
The Brazilian system for dengue/DHF reporting relies
on passive surveillance, with laboratory diagnosis for case
ascertainment and identification of circulating serotypes. A
parallel system for entomologic surveillance exists to
monitor virus and vector dispersion. Analyses of data
reported to the state and national level are used to evaluate
the impact of disease, time trends, and geographic distri-
bution, with the objective of supporting and improving
public health interventions (13). In a previous report, we
analyzed the dengue situation, focusing on the main poli-
cies regarding prevention and control strategies adopted in
Brazil (8). Here, on the basis of national surveillance data,
we analyze the trends of dengue/DHF from the early 1980s
to 2002 and contrast the changes in the epidemiologic pat-
tern of disease for regions in Brazil.
Methods
Brazil is the largest and most populated country in
Latin America, covering >8 million km2 with an estimated
2002 population of 174,632,932 inhabitants. High popula-
tion density areas and cities (up to 12,901 inhabitants/km2)
are located mainly on the Atlantic Coast. Most of Brazil
has a tropical climate; in the southern region, the climate is
subtropical. The rainy season is observed in the first sev-
eral months of the year, and the average temperature is
>20°C (14).
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Dengue/DHF is a reportable disease in Brazil, and the
ministry of health has implemented a surveillance system
since the first epidemic in the early 1980s. We reviewed
available data compiled from 1986 to 2003 by the official
surveillance system. We also used the available computer-
ized data from the Hospitalization Information System of
the Unified Health System (SIH-SUS), which covers
≈70%–80% of overall hospitalizations in the country
(15,16). This system permits recovery of information on
hospital admissions according to the International Disease
Classification system (ICD versions 9 and 10). For this
analysis, we selected hospitalizations due to dengue fever
and DHF stratified by state from 1990 to 2003.
Case Definition and Surveillance Forms
During the study period, case definitions used for sus-
pected, probable, and confirmed dengue/DHF adhered to
PAHO guidelines (17). Information on persons with sus-
pected dengue/DHF is routinely reported by using stan-
dardized forms completed by clinicians or health staff and
subsequently sent to local health surveillance officials for
data checking. This dengue/DHF case investigation form
includes information on basic demographic data, dates of
symptom onset and sample collection, case classification
(dengue fever, DHF, DSS, or discarded case), and out-
come. Individual data are locally entered into the electron-
ic information system and subsequently transmitted to
state and national levels.
Laboratory Confirmation 
and Entomologic Surveillance
Laboratory confirmation was based on the following:
1) serologic tests (immunoglobulin M antibody-capture
enzyme-linked immunosorbent assay) performed on serum
samples collected >6 days after the onset of symptoms
(18); or 2) virus isolation in C6/36 mosquito cell culture
from blood samples collected <6 days after symptom onset
(19). Immunohistochemical studies with formalin-fixed
tissues were performed on samples from selected patients
who died (20). 
Initially, 3 public health laboratories were responsible
for DENV laboratory confirmation: Evandro Chagas
Institute (located in Belém, Pará State), which is the
Ministry of Health reference laboratory; Oswaldo Cruz
Foundation (Rio de Janeiro); and Adolfo Lutz Institute
(São Paulo). During the 1990s, the Public Health
Laboratory Network was set up for the dengue-endemic
states to respond to increasing requests for laboratory con-
firmation. By 2001, a total of 27 public laboratories at state
level were in charge of serologic tests and quality control.
Information on circulating serotypes was obtained from
viral isolation by the 3 national reference laboratories
during the 1980s and subsequently from 13 public health
laboratories at the state level. Laboratory results are rou-
tinely linked to individual data. Classification of DHF
required laboratory confirmation throughout the study
period. Approximately 30% of dengue fever cases are also
laboratory-confirmed. During epidemics, dengue cases
were mostly classified by clinical and epidemiologic
criteria because of limits in laboratory capacity.
The number of municipalities documented with A.
aegypti infestations and information on vector dispersion
were abstracted from data compiled by the national vector
information system for yellow fever and dengue.
Data Analysis
A descriptive analysis of dengue incidence was per-
formed by region (using residence of reported cases) from
1986 to 2002. Incidence and hospitalization rates by age
group were calculated by using census population data as
denominators. The ratio of incident versus hospitalized
cases was also calculated. Exploratory data analysis of the
age group of reported patients focused on data from 1998
to 2002, since standardized data in electronic format for
these variables were available for this period.
Results
The epidemiologic pattern of dengue fever in Brazil
during the last 20 years can be divided into 2 distinct peri-
ods: 1) epidemic waves in localized areas (1986–1993) and
2) epidemic and endemic virus circulation countrywide
(1994–2002) (Figure 1 and Table 1). The main dengue-
related events occurring in these 2 periods are summarized
in Table 1. In 1981, the first laboratory-confirmed cases of
dengue (DENV1 and DENV4) occurred in an isolated area
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Figure 1. Number of dengue fever cases reported per month,
Brazil. A) 1986–1993, B) 1994–2003. Dark bars represent January.  in the northwest Amazon region (Roraima State). After a
5-year interval without confirmed dengue fever, an epi-
demic due to DENV1 occurred in Rio de Janeiro State and
was followed by several epidemics in highly populated
cities in the southeast and northeast regions of Brazil. The
number of dengue fever cases peaked at ≈100,000 in 1987
and 1991, probably because different serotypes (DENV1
and DENV2, respectively; Figure 2) were introduced.
From 1986 to 1993, a total of 76.6% of the 294,419 report-
ed dengue cases occurred in the rainy season from
December to May, showing a marked seasonal pattern
(Figure 1B). A cyclical pattern of 2-year intervals between
large outbreaks was observed, which suggested low viral
activity in the dry season (June to November).
In the second period (1994–2002), a total of 2,826,948
dengue cases were reported, indicating an upward trend in
the incidence from 37 to 454 per 100,000 inhabitants.
Although large outbreaks were observed in the rainy sea-
son, 482,163 cases were reported in the nonrainy season,
which demonstrated increased dengue virus activity during
the entire year. The bulk of incident cases were generated
from metropolitan areas, although several outbreaks
occurred in smaller urban settings in 25 out of 27 states.
Two unprecedented epidemics occurred in 1998 and 2002,
with 528,388 and 794,219 dengue fever cases reported,
respectively. During this second period, vector surveil-
lance to monitor A. aegypti infestation was extended to
most of the country, covering 69.7% (n = 3,878) of the
municipalities in 1996 and 89.6% (n = 4,985) in 2002.
According to this vector information system, the number
of infested municipalities ranged from 1,726 (44.5%) in
1996 to 2,905 (58.3%) in 2002. To date, Santa Catarina
and Rio Grande do Sul States, located in southernmost
Brazil, remain free of autochthonous dengue transmission;
they report only imported cases.
The overall age distribution among reported cases dur-
ing the last 5 years is presented in Figure 3. Approximately
50% of all reported dengue cases occurred in adults 20–40
years of age. During this period, dengue incidence was
consistently higher in adults, reaching up to 432.7/100,000
population in the 30- to 49-year-old age group in 2002
(Table 2). The male:female ratio was constant at ≈1.1:1
during this 5-year period. Sex and age group distribution
were very similar when the data for the 5 regions of the
country were stratified (data not shown).
The first DHF cases were confirmed in 1990, after
DENV2 was introduced into Brazil. During the decade that
followed, 893 confirmed DHF cases with 44 deaths (rate
of 4.9%) occurred; 75% of these deaths occurred in Rio de
Janeiro State. During 2001–2002, a striking increase in the
number of DHF cases was detected, with incidence rates of
2.9/100,000 population (n = 682) in 2001 and 12.9/
100,000 population (n = 2,714) in 2002 (Figure 2). DHF
cases increased 45-fold from 2000 to 2002, compared to a
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Figure 2. Number of reported cases and hospital-
izations due to dengue and dengue hemorrhagic
fever (DHF), Brazil, 1986–2002. 3.3-fold increase in dengue fever cases during the same
period. In the epidemic year of 2002, the overall ratio of
dengue fever to DHF cases was 292.6; in Rio de Janeiro
State, the most affected area, this ratio was 134.8. From
1998 to 2002, the case-fatality rate was 5.4% (195/3,632).
During this period, the sex distribution of DHF was simi-
lar, and cases occurred mainly in adults (median age 33
years) (Figure 3A). Recently, a different pattern in the age
distribution of DHF was observed in Amazonas State,
where unlike the national level, a higher proportion of
DHF cases occurred among children. In Amazonas State,
30.9% (17/55) and 28.8% (15/52) of DHF cases occurred
among children <15 years of age in 2001 and 2003, respec-
tively (Figure 3B).
Countrywide, an upward trend in hospitalized dengue
cases has been apparent since 1994, peaking with >54,000
hospitalizations in 2002 (Figures 2 and 4). Hospitalization
rates were consistently higher among adults from 1998 to
2002. Comparing the 2 largest epidemic years (1998 and
2002), hospitalization rates in all age groups increased
≈8-fold (Table 2). The ratio of reported to hospitalized
cases decreased from 29.4 in 1998 to 10.6 in 2002, which
represents 1 hospitalization for every 10 reported dengue
cases. Despite this increased proportion of hospitalized
cases, >90% of the total reported cases were considered
mild or moderate cases by the health system.
In Brazil, the chronology of the appearance of DENV
serotypes occurred in the following sequence: DENV1 in
1986, DENV2 in 1990, and DENV3 in 2000 (Figure 2).
The simultaneous circulation of these 3 serotypes was first
detected in multiple states during the last 2 years.
Molecular epidemiology of DENV in Brazil has identified
the Caribbean, Jamaican, and Sri Lankan genotypes for the
DENV1, DENV2, and DENV3 viruses, respectively (21).
Discussion
Analysis of 20 years of dengue/DHF surveillance data
showed 2 distinct periods: an initial phase from 1986 to
1993, characterized by localized, sporadic epidemic waves
in urban centers, and a nationwide endemic and epidemic
pattern from 1994 to 2002. In this latter period, several epi-
demics of dengue progressed towards hyperendemicity in
multiple urban centers. Since 1999, dramatic increases in
both the incidence and hospitalizations due to dengue fever
and DHF have occurred, indicating a likely increase in
disease severity in recent years. Changes in surveillance
coverage might explain part of this increase, but this expla-
nation seems unlikely since no major changes were made
in surveillance definitions. The current intense virus trans-
mission pattern can be explained by the number of munic-
ipalities infested with A. aegypti mosquitoes, the mobility
of the population, and the introduction and cocirculation of
3 different virus serotypes (DENV1, 2, and 3).
The epidemiology of dengue in Brazil presents some
unusual features, characterized by dengue/DHF affecting
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Figure 3. Age distribution of dengue fever (DF) and dengue hem-
orrhagic fever (DHF) cases for Brazil and Amazonas State,
1998–2003. Boxes encompass 25th and 75th percentiles. Black
lines within boxes, medians. Outliers not shown. Dashed line, 15
years old. mainly adults, with a predominance of milder infection in
persons treated at outpatient clinics. In contrast, severe
forms of the disease among children requiring hospitaliza-
tion have been described in DHF epidemics in South and
Central American countries (3,22,23). This endemic pat-
tern has also been reported from Southeast Asia in recent
decades (24,25). Cuban children with secondary infection
by DENV2 showed a higher frequency of DHF and DHF-
related deaths during the epidemic of 1981, which had
been preceded by a DENV1 outbreak 4 years earlier (26).
Apparently, similar events in Brazil, which also experi-
enced the sequential introduction of DENV1 (during 1986)
followed by DENV2 4 years later, led to a different out-
come: most reported dengue/DHF occurred in adults.
These findings may be explained by the distinct DENV2
strains circulating in Cuba (New Guinea) and Brazil
(Jamaica) (21,27,28). Another possibility is the underdiag-
nosis of DHF in children in Brazil, although it seems
unlikely that severe clinical manifestations would not like-
ly be misdiagnosed or fail to draw the attention of public
health authorities. 
During the 20-year period examined, dengue/DHF in
Brazil most commonly affected the adult population, even
with the observed increase of dengue/DHF cases. Despite
these findings, current data underscore a different pattern
in the Amazon region, where an increased proportion of
severe cases occurs among children. This finding repre-
sents a warning to pediatric practitioners and health offi-
cials. In the future, if the current intense DENV circulation
persists, Brazil could resemble Southeast Asia, with DHF
occurring mainly in younger age groups.
In 2002, the absolute number of deaths due to DHF
(N = 150) exceeded malaria deaths for the first time in
Brazil, demonstrating that malaria is not the only major
endemic vector-borne disease in this tropical region.
During that year, the largest epidemic yet recorded, includ-
ing 250,000 dengue cases in the metropolitan area of Rio
de Janeiro, caused major public health and political con-
cern (7,8). Hemorrhagic fever and dengue-related deaths
also clustered in this city. These findings probably reflect
the recent introduction and predominance of DENV3,
which suggests a possible role of this serotype in disease
severity and the potential for additional DHF epidemics in
the future (29). Another possible explanation for the
increase in DHF is the association between secondary
infection with disease severity (10); however, routine sur-
veillance data only indicate patients’ immune status. In
addition, some highly urbanized areas have substantial
proportions of the population living in crowded, impover-
ished areas with poor sanitation (30). These complex urban
settings are present in many regions in Brazil, resulting in
a major challenge for vector control activities (8).
Several seroepidemiologic studies in Brazil have
shown that up to 70% of urban populations had previous
dengue infection, outnumbering reported cases. These
results suggest that seroprevalence increases with age and
that subclinical outcomes are a common feature of DENV
exposure (31,32). Access to health services is considered
nearly universal in Brazil, particularly in urban settings;
therefore, dengue/DHF reports should be representative of
the disease in the population. Incidence and hospitalization
rates by age group showed similar patterns when surveil-
lance system and hospitalization database were analyzed.
The consistent patterns of age and sex distribution for all
regions during epidemic and nonepidemic periods also
suggest reliability of these surveillance data. 
The high case-fatality rate for DHF observed in the last
5 years may be due to difficulties in classifying case sever-
ity according to the standard World Health Organization/
PAHO dengue case definition (33). The Brazilian Ministry
of Health has been strongly committed to improving sur-
veillance and patient care in a major effort to reduce
dengue-related deaths (34). The aim of this policy is to rap-
idly identify patients at risk of developing DHF and to ini-
tiate prompt, adequate treatment (e.g., intravenous fluid
infusion) to prevent DSS. As result of this early and effec-
tive replacement of plasma loss, hemoconcentration (one
of the classification criteria for DHF) has become a less
frequently observed event during the course of the disease,
and therefore, a proportion of these cases may not fulfill
DHF criteria. Different applications or interpretations of
this case definition by countries may limit the ability to
make valid comparisons, particularly in Latin America
compared to Southeast Asia (23,33).
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Figure 4. Number of dengue fever–related hospitalizations per
state by year, Brazil, 1990–2002. Each dot represents the number
of hospitalizations due to dengue/dengue hemorrhagic fever for 1
state by year. Source: Hospitalization Information System-Unified
Health System (SIH-SUS). The current epidemiologic trend underscores the impor-
tance of dengue/DHF and the need for long-term improve-
ments in disease control and surveillance in Brazil. We
have described the changing patterns and epidemiologic
profile of dengue/DHF during the last 20 years in one of the
most severely affected countries in the Americas, highlight-
ing the recent increase in disease severity.
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